Trung Huynh
Stock Analyst at UBS
(4.78)
# 100
Out of 5,124 analysts
56
Total ratings
71.05%
Success rate
30.38%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Trung Huynh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $595 → $660 | $776.54 | -15.01% | 5 | Nov 7, 2025 | |
| LLY Eli Lilly and Company | Maintains: Buy | $895 → $1,080 | $1,064.04 | +1.50% | 10 | Nov 7, 2025 | |
| INSM Insmed | Maintains: Buy | $194 → $223 | $175.07 | +27.38% | 9 | Oct 31, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Buy | $29 → $25 | $1.90 | +1,215.79% | 3 | Aug 15, 2025 | |
| AMGN Amgen | Maintains: Neutral | $326 → $317 | $330.17 | -3.99% | 6 | Aug 6, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Buy | $44 → $38 | $26.28 | +44.60% | 2 | May 9, 2025 | |
| PFE Pfizer | Maintains: Neutral | $24 → $25 | $25.43 | -1.69% | 6 | Apr 30, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $60 → $54 | $54.42 | -0.77% | 5 | Apr 11, 2025 | |
| CABA Cabaletta Bio | Maintains: Buy | $10 → $7 | $2.04 | +243.14% | 2 | Apr 1, 2025 | |
| KYTX Kyverna Therapeutics | Initiates: Buy | $13 | $7.94 | +63.73% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $170 → $175 | $204.79 | -14.55% | 2 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $125 → $126 | $108.87 | +15.73% | 3 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $170 | $223.93 | -24.08% | 1 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $9.20 | - | 1 | Mar 23, 2021 |
Regeneron Pharmaceuticals
Nov 7, 2025
Maintains: Neutral
Price Target: $595 → $660
Current: $776.54
Upside: -15.01%
Eli Lilly and Company
Nov 7, 2025
Maintains: Buy
Price Target: $895 → $1,080
Current: $1,064.04
Upside: +1.50%
Insmed
Oct 31, 2025
Maintains: Buy
Price Target: $194 → $223
Current: $175.07
Upside: +27.38%
Jasper Therapeutics
Aug 15, 2025
Maintains: Buy
Price Target: $29 → $25
Current: $1.90
Upside: +1,215.79%
Amgen
Aug 6, 2025
Maintains: Neutral
Price Target: $326 → $317
Current: $330.17
Upside: -3.99%
Celldex Therapeutics
May 9, 2025
Maintains: Buy
Price Target: $44 → $38
Current: $26.28
Upside: +44.60%
Pfizer
Apr 30, 2025
Maintains: Neutral
Price Target: $24 → $25
Current: $25.43
Upside: -1.69%
Bristol-Myers Squibb Company
Apr 11, 2025
Maintains: Neutral
Price Target: $60 → $54
Current: $54.42
Upside: -0.77%
Cabaletta Bio
Apr 1, 2025
Maintains: Buy
Price Target: $10 → $7
Current: $2.04
Upside: +243.14%
Kyverna Therapeutics
Oct 10, 2024
Initiates: Buy
Price Target: $13
Current: $7.94
Upside: +63.73%
Jul 21, 2023
Maintains: Neutral
Price Target: $170 → $175
Current: $204.79
Upside: -14.55%
Mar 7, 2023
Maintains: Outperform
Price Target: $125 → $126
Current: $108.87
Upside: +15.73%
Nov 18, 2022
Initiates: Outperform
Price Target: $170
Current: $223.93
Upside: -24.08%
Mar 23, 2021
Upgrades: Outperform
Price Target: n/a
Current: $9.20
Upside: -